Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / Stem Cells for Heart Failure: Blood Flow and Scarring
Transcript
- 0:00SPEAKER_01: Welcome to the Cyrona Cell Podcast.
- 0:02SPEAKER_00: Glad to be here.
- 0:04SPEAKER_01: So imagine your heart is a car engine and um you've just blown a gasket.
- 0:10SPEAKER_01: You wouldn't just pour experimental oil over it and hope it magically runs perfectly again, would you?
- 0:15SPEAKER_00: No, I mean you definitely wouldn't.
- 0:16SPEAKER_01: That's a guaranteed way to ruin the engine completely.
- 0:19SPEAKER_00: Exactly.
- 0:20SPEAKER_01: But if you are navigating a complex medical condition, you already know the sheer volume of information available online is, well, it's completely overwhelming.
- 0:29SPEAKER_00: Oh, absolutely.
- 0:30SPEAKER_01: You've got journal articles, slick clinic websites, endless patient forums.
- 0:35SPEAKER_01: Trying to figure out what is actually grounded in solid science can feel like a full-time job.
- 0:40SPEAKER_01: So our mission for you today in this deep dive is to basically cut through all of that noise.
- 0:46SPEAKER_01: We are taking a strict, impartial look at what published clinical research actually reports about blood flow, scarring, and heart health.
- 0:54SPEAKER_01: And specifically, we are going to look closely at the data on stem cell therapies.
- 0:59SPEAKER_00: And to do that properly, we have to establish a central reality right here at the very beginning.
- 1:04SPEAKER_00: Like this is the core message of the published evidence we're reviewing today.
- 1:08SPEAKER_01: The baseline.
- 1:08SPEAKER_00: Right.
- 1:09SPEAKER_00: The baseline.
- 1:10SPEAKER_00: Despite all the ongoing research and the dozens of different trials being conducted globally, no trial shows that these cells rebuild a damaged heart.
- 1:20SPEAKER_00: That is the fundamental reality we must operate from.
- 1:22SPEAKER_01: And that reality check is exactly why we're doing this deep dive.
- 1:25SPEAKER_01: Oh, and just a quick note for you listening, from this point forward in our conversation, just to keep things simple and clear, we will just refer to this topic as the cells or cell therapy.
- 1:36SPEAKER_00: Makes sense.
- 1:37SPEAKER_01: Yeah.
- 1:37SPEAKER_01: So our goal today is to give you a reliable guide to navigating this data.
- 1:41SPEAKER_01: But before we can evaluate experimental approaches, we really have to understand the mechanical breakdown that actually happens inside a failing heart.
- 1:48SPEAKER_01: And of course, the foundational treatments that exist today to manage it.
- 1:52SPEAKER_01: Let's unpack the mechanics a bit.
- 1:53SPEAKER_01: Sure.
- 1:54SPEAKER_01: Think of a myocardial infarction, which is just the medical term for a heart attack, as that blown engine gasket we just mentioned.
- 2:01SPEAKER_00: That's a good way to picture it, yeah.
- 2:02SPEAKER_01: Because in a healthy engine, you need flexible moving parts to generate power.
- 2:07SPEAKER_01: But when someone has ischemic heart disease, narrowed arteries literally cut off the blood supply to the heart muscle.
- 2:13SPEAKER_01: So that tissue is starved of oxygen and it gets damaged.
- 2:17SPEAKER_01: The body's emergency response is to replace that dead muscle with scar tissue.
- 2:21SPEAKER_00: And that resulting scar tissue is the critical mechanical issue here because it simply does not contract.
- 2:28SPEAKER_01: It's like replacing that functioning flexible gasket with a stiff, non-moving piece of hard rubber.
- 2:34SPEAKER_00: Exactly.
- 2:34SPEAKER_00: It takes up space in the engine block, but it does absolutely no work.
- 2:38SPEAKER_00: Eventually, having that unmoving scar weakens the heart to the point of heart failure.
- 2:43SPEAKER_00: And heart failure just means the heart cannot pump enough blood to meet the basic daily needs of the body.
- 2:49SPEAKER_01: It just can't keep up.
- 2:50SPEAKER_00: Right.
- 2:51SPEAKER_00: And because of that severe mechanical deficit, standard care is highly structured today.
- 2:57SPEAKER_00: The National Heart, Lung, and Blood Institute, or NHLBI, outlines the established standard care for heart failure.
- 3:05SPEAKER_00: This forms the absolute base of treatment for anyone diagnosed with the condition.
- 3:09SPEAKER_01: Aaron Powell So what does that baseline look like?
- 3:11SPEAKER_00: Well, it involves a combination of approaches.
- 3:14SPEAKER_00: It starts with specific medicines.
- 3:16SPEAKER_00: These are drugs fundamentally designed to manage the load on the heart.
- 3:20SPEAKER_00: You have uh diuretics to remove extra fluid from the body, or medications that relax the blood vessels to lower the pressure the heart has to pump against.
- 3:29SPEAKER_00: Or drugs that intentionally slow the heart rate down just to reduce the overall burden on the muscle.
- 3:34SPEAKER_01: Taking the pressure off the engine, basically.
- 3:37SPEAKER_00: Precisely.
- 3:38SPEAKER_00: Then you have devices, which can include pacemakers to regulate the timing, implants that correct dangerous electrical rhythms, and even mechanical heart pumps for really severe weakness.
- 3:48SPEAKER_01: Wow, okay.
- 3:49SPEAKER_00: Yeah.
- 3:49SPEAKER_00: There's also surgery to repair physical damage.
- 3:52SPEAKER_00: And for the most severe life-threatening cases where all other treatments have failed, a complete heart transplant is the standard.
- 3:59SPEAKER_00: And alongside all of this are mandatory lifestyle changes, consuming much less salt, getting regular monitored activity, and absolutely no smoking.
- 4:08SPEAKER_01: So standard care focuses entirely on managing the plumbing and the electrical load of the heart rather than trying to like rebuild the broken engine block itself.
- 4:18SPEAKER_01: I actually want to pause here and put a massive warning label on what we just discussed.
- 4:22SPEAKER_01: Nobody listening should ever stop, pause, or change their prescribed medicines without their own doctor's direct personal advice.
- 4:29SPEAKER_00: Aaron Powell Never.
- 4:30SPEAKER_00: That is so critical.
- 4:32SPEAKER_01: Those standard treatments are the absolute bedrock of care.
- 4:36SPEAKER_01: The NHLBI does not list the cells among its standard treatments.
- 4:40SPEAKER_01: Cell therapy is strictly experimental.
- 4:43SPEAKER_00: Right.
- 4:43SPEAKER_00: It is an adjunct.
- 4:44SPEAKER_01: Aaron Powell, which is really important context when we look at facilities offering these options globally.
- 4:49SPEAKER_01: For instance, Cyronicel is a regenerative medicine center based in Kuala Lumpur, and it serves both local and international patients.
- 4:57SPEAKER_01: They notably see a lot of patients traveling from Australia and the Middle East for these procedures.
- 5:02SPEAKER_01: But they position their approach entirely as an adjunct to those conventional treatments we just listed, never as a replacement for them.
- 5:10SPEAKER_00: Which is the responsible way to frame it.
- 5:11SPEAKER_01: Exactly.
- 5:13SPEAKER_01: So because standard treatments mostly manage the decline, researchers naturally started looking beyond standard blood pressure pills and started asking: can we somehow alter the environment of the heart or replace that stiff scar?
- 5:26SPEAKER_01: And that brings us to the actual clinical trials.
- 5:29SPEAKER_01: But um, when you look closely at the numbers, things get complicated fast.
- 5:33SPEAKER_01: Let's dive into four specific studies to see what the data actually reveals.
- 5:37SPEAKER_00: Okay, we'll start with the broadest and most comprehensive look we have.
- 5:41SPEAKER_00: In 2016, a Cochrane review analyzed 38 randomized trials involving 1,907 people.
- 5:47SPEAKER_01: Aaron Powell And a Cochrane review is like a really big deal, right?
- 5:51SPEAKER_00: Yeah, it's considered a major benchmark in medical research because it pulls together all the available data to see the big picture, rather than relying on just one isolated experiment.
- 6:01SPEAKER_00: But the finding across those 38 trials was that there was no gain in heart pumping strength.
- 6:07SPEAKER_01: Wow.
- 6:07SPEAKER_00: From almost 2,000 people.
- 6:09SPEAKER_01: Right.
- 6:10SPEAKER_00: Furthermore, the authors rated the overall evidence as low quality.
- 6:13SPEAKER_01: Why low quality?
- 6:15SPEAKER_00: This was due to significant concerns about bias in the individual studies and the surprisingly small number of clinical events actually recorded during the follow-up periods.
- 6:24SPEAKER_00: Then we also have a major trial from 2020.
- 6:28SPEAKER_00: This one involved 375 people who were given bone marrow cells shortly after a heart attack.
- 6:34SPEAKER_01: Okay.
- 6:34SPEAKER_01: And what happened there?
- 6:36SPEAKER_00: The result after tracking these patients for two full years was that deaths were similar in both the treated group and the untreated control group.
- 6:43SPEAKER_00: There was absolutely no survival benefit shown.
- 6:46SPEAKER_01: Okay, so if bone marrow cells didn't work in 2020, did researchers test different cells or, you know, different delivery methods in other trials?
- 6:54SPEAKER_00: Aaron Powell They did.
- 6:55SPEAKER_00: We have a 2012 trial that involved 30 people.
- 6:59SPEAKER_00: In this study, doctors took mesenchymal cells and injected them directly into the heart wall itself.
- 7:04SPEAKER_01: Right into the muscle.
- 7:06SPEAKER_00: Yeah.
- 7:06SPEAKER_00: And then we have the more recent 2026 trial involving 40 people.
- 7:10SPEAKER_00: In this case, patients were given donor umbilical cord cells and they were delivered by vein, completely changing the approach.
- 7:18SPEAKER_01: Okay.
- 7:18SPEAKER_00: The result of that 2026 trial, however, was no improvement in left side pumping function.
- 7:24SPEAKER_01: Aaron Powell Wait, I have a totally logical question on behalf of anyone listening who is just trying to make sense of this math.
- 7:30SPEAKER_01: You're telling me we have dozens of these trials over the last decade with over 1,900 people in the 2016 review plus 375 in the 2020 trial and dozens more in the others.
- 7:41SPEAKER_01: Why can't the scientific community just agree on one standard way to deliver these cells?
- 7:46SPEAKER_01: Or at the very least, why can't researchers just add all these results together to get one definitive, mathematically solid answer about whether this works?
- 7:54SPEAKER_00: Aaron Powell Because it's the ultimate apples and oranges problem in medical research.
- 7:59SPEAKER_00: You simply cannot pool the results because the methodology fluctuates wildly from one trial to the next.
- 8:05SPEAKER_01: How so?
- 8:05SPEAKER_00: Every single study used a completely different cell type, they used vastly different doses, and they used entirely different delivery routes.
- 8:13SPEAKER_00: You cannot mathematically combine the outcome of a trial that used bone marrow cells injected straight into a beating heart muscle with the outcome of a completely different trial that dripped donor umbilical cord cells through an intravenous lime.
- 8:27SPEAKER_00: The biological variables are simply too disjointed to merge.
- 8:31SPEAKER_01: That makes sense.
- 8:32SPEAKER_01: But if the overall pumping strength isn't improving, as that massive 2016 review showed, maybe we need to look at the micro level.
- 8:39SPEAKER_01: I mean, are the cells somehow changing the internal environment of the heart muscle?
- 8:44SPEAKER_01: Specifically, could they be improving blood flow or shrinking those stiff rubber scars we talked about earlier?
- 8:49SPEAKER_00: Aaron Powell Well, on the crucial question of blood flow, the published data is remarkably silent.
- 8:54SPEAKER_01: Really?
- 8:55SPEAKER_01: Silent.
- 8:55SPEAKER_00: None of the four studies we just walked through reports a direct measure of new blood flow to the heart.
- 9:00SPEAKER_00: They do not report on new blood vessel growth.
- 9:03SPEAKER_00: Therefore, whether cell therapy actually improves blood supply to the heart remains an entirely open research question.
- 9:09SPEAKER_00: The data assembly isn't there to support it.
- 9:11SPEAKER_01: Aaron Powell But let's look at the scarring, because there is a fascinating nuance in the data here.
- 9:16SPEAKER_01: You mentioned the 2012 trial with 30 people where they injected the cells directly into the heart wall.
- 9:22SPEAKER_01: That trial actually reported smaller scars on the patient's scans.
- 9:26SPEAKER_00: It did, yes.
- 9:26SPEAKER_01: So if researchers are seeing smaller scars on an MRI, isn't that the aha moment?
- 9:31SPEAKER_01: Doesn't that prove the therapy is doing something beneficial?
- 9:34SPEAKER_00: It requires deep critical analysis, actually, because that 2012 trial carries two major red flags that completely change how we interpret those scans.
- 9:42SPEAKER_00: First, the trial had no placebo group.
- 9:45SPEAKER_01: Oh.
- 9:46SPEAKER_00: Yeah.
- 9:46SPEAKER_00: When you don't have a control group receiving a placebo, you cannot definitively conclude that the cells are what cause the smaller scars.
- 9:53SPEAKER_00: The human body is dynamic, and other factors could easily be at play.
- 9:58SPEAKER_00: Second, and perhaps much more importantly, we have to look at how the heart actually functioned mechanically.
- 10:04SPEAKER_01: The pumping strength?
- 10:05SPEAKER_00: Right.
- 10:06SPEAKER_00: The 2016 Cochrane review showed no clear gain in pumping strength across its massive pool of data.
- 10:12SPEAKER_00: And that 2012 trial itself showed no gain in exercise capacity, which they measured objectively by looking at peak oxygen use during physical activity.
- 10:20SPEAKER_01: So the scan might show a smaller scar, but the patient's engine is still failing to generate more power when they try to actually get up and walk or exercise.
- 10:31SPEAKER_00: Exactly.
- 10:31SPEAKER_00: Structural changes on a visual scan may not translate into actual functional improvement for the heart.
- 10:37SPEAKER_00: If the patient cannot use more oxygen or pump more blood during their daily life, the mathematically smaller scar in an MRI doesn't change the reality of their heart failure.
- 10:46SPEAKER_01: That's a huge distinction.
- 10:48SPEAKER_01: And the mixed results make a lot of sense when you realize how many massive biological variables are in play here.
- 10:54SPEAKER_01: It's really crucial for you to understand exactly how these experimental treatments are administered and the very real risks involved in tweaking the heart's environment.
- 11:03SPEAKER_01: Let's talk about the delivery routes and the specific cell types because they are completely all over the map.
- 11:09SPEAKER_00: Aaron Powell They really are.
- 11:10SPEAKER_00: The methods are completely non-standardized across the field.
- 11:14SPEAKER_00: Across the trials, researchers used mixed bone marrow cells, bone marrow mesenchymal cells, and umbilical cord mesenchymal cells.
- 11:22SPEAKER_00: And the way they physically delivered them into the body was just as varied.
- 11:26SPEAKER_01: Aaron Powell Like IV versus injection.
- 11:28SPEAKER_00: Right.
- 11:29SPEAKER_00: In the 2026 trial, they gave the umbilical cord cells by vein.
- 11:34SPEAKER_00: They administered them three separate times, spacing the doses six weeks apart, and tracked the people for 360 days.
- 11:42SPEAKER_00: Compare that to the 2012 trial, where doctors literally took a needle and injected the cells directly into ten different spots of the heart's main pumping chamber.
- 11:52SPEAKER_01: That is wildly different.
- 11:54SPEAKER_01: And regarding the cell types, this is actually a good place to mention the specific operations of the Cirrona cell team.
- 12:00SPEAKER_01: They state that their program uses umbilical cord-derived Wharton's Jelly MSCs, which they process to BSL2, CGMP, and ISO 9001 standards.
- 12:11SPEAKER_00: Aaron Powell Lots of acronyms there.
- 12:12SPEAKER_00: Trevor Burrus, Jr.
- 12:12SPEAKER_01: Lots of acronyms, which just to translate those into plain English for anyone listening, basically means they follow strict manufacturing and quality control protocols.
- 12:21SPEAKER_01: Kind of similar to how a high-end pharmaceutical lab would ensure their facility is clean and their procedures are documented.
- 12:28SPEAKER_00: And it's imperative to understand that these are the center's own statements about their laboratory processing standards.
- 12:34SPEAKER_00: Having a clean, standardized lab is important for safety, definitely, but those statements must never be taken as proof of clinical benefit in heart failure.
- 12:42SPEAKER_01: Right.
- 12:43SPEAKER_01: Good point.
- 12:44SPEAKER_00: Furthermore, those acronyms are not a statement of regulatory approval for the treatment itself.
- 12:49SPEAKER_00: The published scientific evidence does not rank cell sources, and it certainly does not suggest that umbilical cord cells are somehow superior to bone marrow or other sources for treating heart failure.
- 13:00SPEAKER_01: Aaron Powell Good to clarify.
- 13:02SPEAKER_01: And we absolutely cannot discuss experimental medical treatments without discussing safety.
- 13:07SPEAKER_01: What are the documented risks of participating in these trials?
- 13:10SPEAKER_01: Because poking a needle into a beating heart or dumping foreign cells into the bloodstream, that can't be risk-free.
- 13:16SPEAKER_00: Aaron Powell It isn't.
- 13:17SPEAKER_00: The reported risks are serious, and they differ depending on the specific trial.
- 13:22SPEAKER_00: In the 2020 trial of 375 people given bone marrow cells after a heart attack, there were four strokes reported in the treated group.
- 13:30SPEAKER_01: And the control group?
- 13:31SPEAKER_00: There were zero strokes in the control group.
- 13:33SPEAKER_00: Wow.
- 13:34SPEAKER_00: Then in the 2026 trial involving 40 people, the patients receiving the cells by vein had higher levels of D-dimer.
- 13:41SPEAKER_00: A D-dimer is a biomarker in the blood that indicates active clotting.
- 13:45SPEAKER_01: But why would that happen?
- 13:46SPEAKER_01: How does introducing cells through an IV lead to clotting markers or strokes?
- 13:51SPEAKER_00: Aaron Powell Well, when you introduce foreign cells into the bloodstream by vein, the body's coagulation system can sometimes react to them as if they were debris or an injury that needs to be plugged.
- 14:01SPEAKER_00: This triggers a clotting cascade.
- 14:03SPEAKER_00: So higher D-dimer means the body is actively forming and breaking down clots.
- 14:08SPEAKER_00: If one of those microscopic clots travels to the brain, that results in a stroke.
- 14:13SPEAKER_01: That is terrifying.
- 14:15SPEAKER_00: It's a real risk.
- 14:16SPEAKER_00: And the most significant unknown hanging over all of this research is sample size.
- 14:21SPEAKER_00: Every single trial conducted so far has simply been too small to definitively rule out these rare but severe harms.
- 14:29SPEAKER_00: We are operating in the dark on several major fronts.
- 14:32SPEAKER_01: Aaron Powell What are the biggest unknowns right now?
- 14:35SPEAKER_00: The optimal dose, the safest delivery route, and the most effective cell source.
- 14:39SPEAKER_00: They remain complete unknowns.
- 14:42SPEAKER_00: Before anyone can make broad claims about safety or efficacy, much larger trials with significantly longer follow-up periods are absolutely needed to assess how this actually impacts survival rates, the frequency of hospital stays, and the patient's overall quality of life over the long term.
- 14:58SPEAKER_01: So knowing that the massive Cochrane review rated the overall evidence as low quality, and knowing all these lingering unknowns surrounding the dose and the clotting risks, it puts a really heavy burden on you, the patient.
- 15:12SPEAKER_01: If you're weighing your options or looking at traveling internationally to a clinic, how do you protect yourself?
- 15:18SPEAKER_01: You have to demand total transparency.
- 15:20SPEAKER_00: You really do.
- 15:21SPEAKER_01: It is incredibly easy to be swayed by a slick presentation or verbal promises in a consulting room.
- 15:27SPEAKER_01: So we want to give you a highly practical, empowering checklist.
- 15:31SPEAKER_01: These are the specific questions you must ask a treating team and you must get the answers in writing before you ever agree to a visit.
- 15:50SPEAKER_01: Because if the answer is none, you need to know that.
- 15:53SPEAKER_00: Exactly.
- 15:54SPEAKER_00: Second, how will the cells physically be given and how many doses are planned?
- 15:59SPEAKER_00: Third, what written batch tests does the lab run?
- 16:03SPEAKER_00: For example, do they perform specific Wharton's jelly quality testing before the treatment is administered?
- 16:09SPEAKER_01: And you also need the logistical and safety details locked down just as tightly.
- 16:13SPEAKER_00: Yes.
- 16:14SPEAKER_00: You must ask, who is the specific treating doctor performing the procedure?
- 16:18SPEAKER_00: What are the written risks, the step-by-step follow-up plan, and the total final cost?
- 16:24SPEAKER_00: And finally, a crucial question for continuity of care: how will your own heart doctor back home receive the follow-up results and the medical records?
- 16:33SPEAKER_01: This rigorous checklist applies to any offer of cell therapy for the heart, anywhere in the world.
- 16:38SPEAKER_01: And that includes the partner facilities in Kuala Lumpur, where the treating doctors give treatment for the Cirrona cell team.
- 16:44SPEAKER_01: It is your absolute right as a patient to have these answers documented in writing.
- 16:50SPEAKER_01: Don't accept verbal assurances when you're dealing with experimental procedures on something as vital as your heart.
- 16:56SPEAKER_00: Transparency is non-negotiable in experimental medicine.
- 16:59SPEAKER_01: It really is.
- 17:00SPEAKER_01: Let's bring this all together and reiterate the core evidence-based takeaway from the sources we reviewed today.
- 17:07SPEAKER_01: Cell therapy remains an experimental adjunct to conventional care.
- 17:11SPEAKER_01: Despite all the ongoing research and the different trials, no trial has shown that it actually rebuilds a failing heart.
- 17:19SPEAKER_01: If you or a loved one are managing heart failure, we strongly encourage you to talk with your own heart doctor.
- 17:25SPEAKER_01: Have an honest, grounded conversation about realistic goals, what standard treatments can reliably do, and what the latest evidence actually reveals about experimental options.
- 17:42SPEAKER_00: This trial involved bypass patients.
- 17:44SPEAKER_00: And instead of the adult cells we've been discussing today, researchers decided to try using lab grown heart muscle cells.
- 17:50SPEAKER_01: Oh, interesting.
- 17:51SPEAKER_00: Yeah.
- 17:52SPEAKER_00: And the results were fascinating.
- 17:53SPEAKER_00: Blood flow actually did improve.
- 17:56SPEAKER_00: The patient's walking distance improved.
- 17:59SPEAKER_00: However, every single one of the ten treated patients developed an abnormal heart rhythm.
- 18:05SPEAKER_01: Wait, all ten of them?
- 18:07SPEAKER_00: A hundred percent.
- 18:08SPEAKER_01: Every single one?
- 18:09SPEAKER_00: Every single one.
- 18:10SPEAKER_01: That isn't just a minor side effect.
- 18:12SPEAKER_01: That completely defeats the purpose of trying to fix the heart in the first place if you're destroying its rhythm.
- 18:17SPEAKER_00: It is a profoundly sobering reminder.
- 18:19SPEAKER_01: Yeah.
- 18:19SPEAKER_00: Trying to mechanically fix the heart with new cells might improve one specific metric, like blood flow, but it can unexpectedly disrupt the heart's delicate electrical system in the process.
- 18:29SPEAKER_00: It shows just how incredibly complex human biology truly is and why we have to proceed with such caution.
- 18:36SPEAKER_01: It goes right back to our engine analogy.
- 18:38SPEAKER_01: You can't just patch a blown gasket with experimental materials and expect the engine to run perfectly, especially if those new materials end up short circuiting the entire electrical system of the car.
- 18:48SPEAKER_01: Thank you for joining us as we navigated this complex data today.
- 18:52SPEAKER_01: Stay curious, always ask the hard questions in writing, and always consult your doctor.